틀:인간의 체온

참고 문헌

↑ Marx, John (2006). 《Rosen's emergency medicine: concepts and clinical practice》. Mosby/Elsevier. 2239쪽. ISBN 978-0-323-02845-5.
↑ Hutchison, James S.; 외. (June 2008). “Hypothermia therapy after traumatic brain injury in children”. 《New England Journal of Medicine》 358 (23): 2447–2456. doi:10.1056/NEJMoa0706930. PMID 18525042.
↑ Pryor, Jennifer A.; Prasad, Ammani S. (2008). 《Physiotherapy for Respiratory and Cardiac Problems: Adults and Paediatrics》 (영어). Elsevier Health Sciences. 8쪽. ISBN 0702039748.
↑ ^가 ^나 Axelrod, Yekaterina K.; Diringer, Michael N. (May 2008). “Temperature management in acute neurologic disorders”. 《Neurologic Clinics》 26 (2): 585–603, xi. doi:10.1016/j.ncl.2008.02.005. PMID 18514828.
↑ ^가 ^나 Laupland, Kevin B. (July 2009). “Fever in the critically ill medical patient”. 《Critical Care Medicine》 37 (7 Suppl): S273–8. doi:10.1097/CCM.0b013e3181aa6117. PMID 19535958.
↑ Grunau, Brian E.; Wiens, Matthew O.; Brubacher, Jeffrey R. (September 2010). “Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review”. 《Canadian Journal of Emergency Medicine》 12 (5): 435–442. doi:10.1017/s1481803500012598. PMID 20880437. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42 °C) or severe (≥ 40 °C) hyperpyrexia
↑ Sharma, Hari Shanker, 편집. (2007). 《Neurobiology of Hyperthermia》 1판. Elsevier. 175–177, 485쪽. ISBN 9780080549996. 2016년 11월 19일에 확인함. Despite the myriad of complications associated with heat illness, an elevation of core temperature above 41.0 °C (often referred to as fever or hyperpyrexia) is the most widely recognized symptom of this syndrome.

[Rosen-1] Marx, John (2006). 《Rosen's emergency medicine: concepts and clinical practice》. Mosby/Elsevier. 2239쪽. ISBN 978-0-323-02845-5.

[pmid18788094-2] Hutchison, James S.; 외. (June 2008). “Hypothermia therapy after traumatic brain injury in children”. 《New England Journal of Medicine》 358 (23): 2447–2456. doi:10.1056/NEJMoa0706930. PMID 18525042.

[3] Pryor, Jennifer A.; Prasad, Ammani S. (2008). 《Physiotherapy for Respiratory and Cardiac Problems: Adults and Paediatrics》 (영어). Elsevier Health Sciences. 8쪽. ISBN 0702039748.

[NC08-4] 가 ^나 Axelrod, Yekaterina K.; Diringer, Michael N. (May 2008). “Temperature management in acute neurologic disorders”. 《Neurologic Clinics》 26 (2): 585–603, xi. doi:10.1016/j.ncl.2008.02.005. PMID 18514828.

[CC09-5] 가 ^나 Laupland, Kevin B. (July 2009). “Fever in the critically ill medical patient”. 《Critical Care Medicine》 37 (7 Suppl): S273–8. doi:10.1097/CCM.0b013e3181aa6117. PMID 19535958.

[6] Grunau, Brian E.; Wiens, Matthew O.; Brubacher, Jeffrey R. (September 2010). “Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review”. 《Canadian Journal of Emergency Medicine》 12 (5): 435–442. doi:10.1017/s1481803500012598. PMID 20880437. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42 °C) or severe (≥ 40 °C) hyperpyrexia

[7] Sharma, Hari Shanker, 편집. (2007). 《Neurobiology of Hyperthermia》 1판. Elsevier. 175–177, 485쪽. ISBN 9780080549996. 2016년 11월 19일에 확인함. Despite the myriad of complications associated with heat illness, an elevation of core temperature above 41.0 °C (often referred to as fever or hyperpyrexia) is the most widely recognized symptom of this syndrome.

[1]

[2]

[3]

[4]

[5]

[6]

[7]